Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Omacor plus Atorvastatin in Type IIb Dyslipidemia
NCT02035215Phase 3Unknown
- Sponsor
- Kuhnil Pharmaceutical
- Start
- Jan 2014
- Primary completion
- Oct 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Familial Combined Hyperlipidemia (FCH) comparing Omacor + Atorvastatin with Atorvastatin + Placebo (2 arms). Primary endpoint: Triglyceride at 8 weeks. Status: unknown.
02
Drugs
omega-3-acid triglycerides
03
Conditions
Familial Combined Hyperlipidemia (FCH)
Beyond the preview
Go deeper on NCT02035215.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02035215.